Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,177.01
(
-0.48%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 146447

Monday, 12/02/2013 12:58:21 PM

Monday, December 02, 2013 12:58:21 PM

Post# of 257268
(HALO)—BAX resubmits BLA for HyQvia (enhanced IVIG):

http://finance.yahoo.com/news/baxter-submits-amended-bla-u-140000366.html

HyQvia is a combination of human immune globulin and recombinant human hyaluronidase. Baxter and Halozyme submitted additional preclinical data that was requested from the FDA in [August] 2012, and expect a six-month review period.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now